Abstract
Abstract
Coronavirus disease 2019 (COVID-19) is associated with autoimmunity and systemic inflammation. Patients with autoimmune rheumatic and musculoskeletal disease (RMD) may be at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, based on evidence from the literature, as well as international scientific recommendations, we review the relationships between COVID-19, autoimmunity and patients with autoimmune RMDs, as well as the basics of a multisystemic inflammatory syndrome associated with COVID-19. We discuss the repurposing of pharmaceutics used to treat RMDs, the principles for the treatment of patients with autoimmune RMDs during the pandemic and the main aspects of vaccination against SARS-CoV-2 in autoimmune RMD patients.
Publisher
Cambridge University Press (CUP)
Subject
Molecular Biology,Molecular Medicine
Reference90 articles.
1. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19
2. Effective treatment of severe COVID-19 patients with tocilizumab
3. Antiphospholipid Antibodies in Critically Ill Patients With COVID‐19
4. 21. American College of Rheumatology (2020) COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases. Available at https://wwwrheumatologyorg/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseasespdf.
5. 66. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 (2020) http://fdagov. Epub 2020 Nov 19.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献